Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) have received a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $20.00.
A number of research analysts have commented on the stock. Robert W. Baird assumed coverage on shares of Larimar Therapeutics in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $16.00 price objective on the stock. Baird R W raised Larimar Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 4th.
Read Our Latest Research Report on LRMR
Institutional Inflows and Outflows
Larimar Therapeutics Stock Up 3.8 %
Shares of NASDAQ LRMR opened at $6.57 on Friday. The stock has a market cap of $419.23 million, a PE ratio of -6.77 and a beta of 0.99. Larimar Therapeutics has a 52-week low of $2.18 and a 52-week high of $13.68. The business has a 50-day moving average price of $7.76 and a 200 day moving average price of $7.88.
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.02). Sell-side analysts anticipate that Larimar Therapeutics will post -1.4 earnings per share for the current year.
Larimar Therapeutics Company Profile
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
See Also
- Five stocks we like better than Larimar Therapeutics
- What is an Earnings Surprise?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What is Short Interest? How to Use It
- MarketBeat Week in Review – 9/23 – 9/27
- How to Buy Cheap Stocks Step by Step
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.